Lupin Limited has informed the Exchange regarding a press release dated September 17, 2025, titled "Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has received approval from the U.S. FDA to market Lenalidomide Capsules in the United States. Lenalidomide is a generic equivalent of Bristol-Myers Squibb's Revlimid, used primarily in the treatment of multiple myeloma and other blood-related conditions. The approval enables Lupin to manufacture and commercially sell this product in the lucrative U.S. generic market. This adds to Lupin's growing portfolio of oncology and complex generic products. The company had already been a significant player in the U.S. generics space, and this approval strengthens its oncology franchise.
Positive for the company — U.S. FDA approvals for high-value generics like Lenalidomide can unlock meaningful new revenue streams. Shareholders may see this as a value-adding development, though actual sales impact will depend on market share gains and competition.